11,279 Shares in GSK plc (NYSE:GSK) Purchased by Potentia Wealth

Potentia Wealth acquired a new stake in GSK plc (NYSE:GSK) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 11,279 shares of the pharmaceutical company’s stock, valued at approximately $381,000.

Several other institutional investors have also added to or reduced their stakes in GSK. United Bank lifted its stake in shares of GSK by 7.3% during the 3rd quarter. United Bank now owns 25,785 shares of the pharmaceutical company’s stock valued at $1,054,000 after buying an additional 1,760 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in shares of GSK by 3.4% during the third quarter. Thrivent Financial for Lutherans now owns 53,348 shares of the pharmaceutical company’s stock worth $2,181,000 after acquiring an additional 1,737 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of GSK by 13.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 121,603 shares of the pharmaceutical company’s stock worth $4,971,000 after acquiring an additional 14,687 shares during the period. Cerity Partners LLC grew its position in shares of GSK by 61.8% in the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock valued at $17,728,000 after purchasing an additional 165,556 shares in the last quarter. Finally, Larson Financial Group LLC raised its stake in shares of GSK by 527.4% during the 3rd quarter. Larson Financial Group LLC now owns 1,807 shares of the pharmaceutical company’s stock valued at $74,000 after purchasing an additional 1,519 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Morgan Stanley started coverage on GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Down 1.7 %

Shares of NYSE GSK opened at $38.58 on Tuesday. The stock has a market capitalization of $79.86 billion, a P/E ratio of 24.27, a PEG ratio of 1.12 and a beta of 0.58. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. GSK plc has a one year low of $31.72 and a one year high of $45.93. The firm’s 50 day simple moving average is $36.77 and its two-hundred day simple moving average is $36.84.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, analysts expect that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. This is a boost from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a yield of 4.08%. The ex-dividend date is Friday, February 21st. GSK’s payout ratio is 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.